MedPage Today recently asked an important question: if antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), rapid diagnostics, and decades of implementation science exist, why has the HIV epidemic not ended? The article correctly identifies political leadership, funding instability, stigma, and weakening public health infrastructure as major contributors. Those observations are accurate -- but they are incomplete.
The next chapter in HIV prevention should not be written primarily in pharmacology laboratories. It should be written by healthcare managers, implementation scientists, clinicians, public health leaders, and policymakers willing to redesign the systems through which people encounter prevention and care.
The central problem is no longer biomedical efficacy. Modern antiretroviral therapy transforms HIV into a manageable chronic condition, while PrEP and PEP dramatically reduce transmission when used appropriately. The persistent challenge is implementation. Biomedical innovation has outpaced health system innovation.
Healthcare has traditionally conceptualized HIV through a linear continuum: testing, diagnosis, linkage to care, treatment, retention, and viral suppression. While useful, this framework overlooks a more fundamental reality: every stage represents a decision that patients must navigate inside a healthcare environment.
